Cargando…

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

The aim of this study was to determine an optimal workflow to detect TP53 mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients and to define whether TP53 mutations are suitable as biomarker for disease. TP53 was investigated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitale, Silvia R., Groenendijk, Floris H., van Marion, Ronald, Beaufort, Corine M., Helmijr, Jean C., Jan Dubbink, Hendrikus, N. M. Dinjens, Winand, Ewing-Graham, Patricia C., Smolders, Ramon, van Doorn, Helena C., Boere, Ingrid A., Berns, Els M. J. J., Helleman, Jozien, Jansen, Maurice P. H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175353/ https://www.ncbi.nlm.nih.gov/pubmed/32156073 http://dx.doi.org/10.3390/biom10030415

Ejemplares similares

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
por: Groenendijk, Floris H., et al.
Publicado: (2010)

Mismatch repair and treatment resistance in ovarian cancer
por: Helleman, Jozien, et al.
Publicado: (2006)

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020)

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
por: Beaufort, Corine M., et al.
Publicado: (2014)

“The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology”: letter to the Editor
por: Dinjens, Winand N. M., et al.
Publicado: (2020)

Mucinous carcinoid of the ovary: report of a case with metastasis in the contralateral ovary after ten years
por: Buis, Christien C.M, et al.
Publicado: (2010)

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma
por: van der Leest, Cor, et al.
Publicado: (2018)

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma
por: Trinh, Xuan Bich, et al.
Publicado: (2011)

Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers
por: Eikenboom, Ellis L., et al.
Publicado: (2021)

Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA
por: Weerts, Marjolein J. A., et al.
Publicado: (2017)

Mitochondrial D310 mutation as clonal marker for solid tumors
por: Geurts-Giele, Willemina R. R., et al.
Publicado: (2015)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory
por: Van Lier, Margot GF, et al.
Publicado: (2010)

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics
por: Synhaeve, Nathalie E., et al.
Publicado: (2018)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

Unexplained mismatch repair deficiency: Case closed
por: Eikenboom, Ellis L., et al.
Publicado: (2022)

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
por: Groenendijk, Floris H., et al.
Publicado: (2019)

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
por: van Jaarsveld, Marijn T. M., et al.
Publicado: (2015)

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma
por: Wijnenga, Maarten M. J., et al.
Publicado: (2018)

Prevalence of c-KIT Mutations in Gonadoblastoma and Dysgerminomas of Patients with Disorders of Sex Development (DSD) and Ovarian Dysgerminomas
por: Hersmus, Remko, et al.
Publicado: (2012)

Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis
por: Spoor, Jonathan, et al.
Publicado: (2021)

Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing
por: Pruis, Melinda A., et al.
Publicado: (2022)

Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
por: Bos, Manouk K., et al.
Publicado: (2020)

Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors
por: van de Beek, Irma, et al.
Publicado: (2022)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

In‐depth molecular analysis of combined and co‐primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma
por: Hermans, Bregtje C. M., et al.
Publicado: (2021)

Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups
por: Wijnenga, Maarten M J, et al.
Publicado: (2019)

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
por: van Doeveren, Thomas, et al.
Publicado: (2020)

Functional Polymorphisms Associated with Disease-Free Survival in Resected Carcinoma of the Esophagus
por: Boonstra, Jurjen J., et al.
Publicado: (2010)

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics
por: Eijkelenboom, Astrid, et al.
Publicado: (2019)

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis
por: Ramirez-Ardila, Diana, et al.
Publicado: (2017)

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
por: Venkatesan, Subramanian, et al.
Publicado: (2016)

Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices
por: Kinsella, Netty, et al.
Publicado: (2018)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

ATRX Loss in the Development and Prognosis of Conjunctival Melanoma
por: van Ipenburg, Jolique A., et al.
Publicado: (2023)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020)

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
por: Berns, E. M., et al.
Publicado: (1998)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Early onset esophageal adenocarcinoma: a distinct molecular entity?
por: van Nistelrooij, Anna M.J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3h3tmc9d6b0hludf89he237akg